| TOX is a critical regulator of tumour-specific T cell differentiation AC Scott, F Dündar, P Zumbo, SS Chandran, CA Klebanoff, M Shakiba, ... Nature 571 (7764), 270-274, 2019 | 966 | 2019 |
| Consensus guidelines for the definition, detection and interpretation of immunogenic cell death L Galluzzi, I Vitale, S Warren, S Adjemian, P Agostinis, AB Martinez, ... Journal for immunotherapy of cancer 8 (1), e000337, 2020 | 964 | 2020 |
| Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy D Zamarin, RB Holmgaard, SK Subudhi, JS Park, M Mansour, P Palese, ... Science translational medicine 6 (226), 226ra32-226ra32, 2014 | 809 | 2014 |
| Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 RB Holmgaard, D Zamarin, DH Munn, JD Wolchok, JP Allison Journal of Experimental Medicine 210 (7), 1389-1402, 2013 | 733 | 2013 |
| Influenza A virus PB1-F2 protein contributes to viral pathogenesis in mice D Zamarin, MB Ortigoza, P Palese Journal of virology 80 (16), 7976-7983, 2006 | 655 | 2006 |
| A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence GM Conenello, D Zamarin, LA Perrone, T Tumpey, P Palese PLoS pathogens 3 (10), e141, 2007 | 640 | 2007 |
| A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity L Glaser, J Stevens, D Zamarin, IA Wilson, A García-Sastre, TM Tumpey, ... Journal of virology 79 (17), 11533-11536, 2005 | 524 | 2005 |
| Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1 D Zamarin, A García-Sastre, X Xiao, R Wang, P Palese PLoS pathogens 1 (1), e4, 2005 | 522 | 2005 |
| Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner RB Holmgaard, D Zamarin, Y Li, B Gasmi, DH Munn, JP Allison, ... Cell reports 13 (2), 412-424, 2015 | 494 | 2015 |
| Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient A Jiménez-Sánchez, D Memon, S Pourpe, H Veeraraghavan, Y Li, ... Cell 170 (5), 927-938. e20, 2017 | 483 | 2017 |
| Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ... Cell 185 (3), 563-575. e11, 2022 | 445 | 2022 |
| IRE1α–XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity M Song, TA Sandoval, CS Chae, S Chopra, C Tan, MR Rutkowski, ... Nature 562 (7727), 423-428, 2018 | 349 | 2018 |
| Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine LF Campesato, S Budhu, J Tchaicha, CH Weng, M Gigoux, IJ Cohen, ... Nature communications 11 (1), 4011, 2020 | 313 | 2020 |
| Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study D Zamarin, RA Burger, MW Sill, DJ Powell Jr, HA Lankes, MD Feldman, ... Journal of Clinical Oncology 38 (16), 1814-1823, 2020 | 301 | 2020 |
| Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions D Zamarin, P Palese Future microbiology 7 (3), 347-367, 2012 | 297 | 2012 |
| Attenuation of equine influenza viruses through truncations of the NS1 protein M Quinlivan, D Zamarin, A García-Sastre, A Cullinane, T Chambers, ... Journal of virology 79 (13), 8431-8439, 2005 | 294 | 2005 |
| Nuclear localization of the Nipah virus W protein allows for inhibition of both virus-and toll-like receptor 3-triggered signaling pathways ML Shaw, WB Cardenas, D Zamarin, P Palese, CF Basler Journal of virology 79 (10), 6078-6088, 2005 | 238 | 2005 |
| Pharmacologic modulation of RNA splicing enhances anti-tumor immunity SX Lu, E De Neef, JD Thomas, E Sabio, B Rousseau, M Gigoux, DA Knorr, ... Cell 184 (15), 4032-4047. e31, 2021 | 213 | 2021 |
| Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer KM Boehm, EA Aherne, L Ellenson, I Nikolovski, M Alghamdi, ... Nature cancer 3 (6), 723-733, 2022 | 204 | 2022 |
| Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy A Jiménez-Sánchez, P Cybulska, KLV Mager, S Koplev, O Cast, ... Nature Genetics 52 (6), 582-593, 2020 | 198 | 2020 |
Carol Aghajanian, MDChief, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer CenterEmail được xác minh tại mskcc.org